Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma, drawn from the whole corpus: 15 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Predicting aggressive behaviour at diagnosis: lineage, Ki-67 and molecular markers are being combined into risk scores.
Salvage after temozolomide: PRRT, immunotherapy and bevacizumab have only case-series evidence.
Hypopituitarism and visual loss from tumour and treatment: radiosurgery and surgical technique aim to reduce them.
Incidentalomas: how to avoid overtreatment of the many small tumours found on imaging.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 17 changes by month →When this page itself was last checked or edited.
Cabergoline first line, titrated to normal prolactin and tumour shrinkage; surgery for resistance, intolerance or pituitary apoplexy.
Lineage-based classification.
Endogenous Cushing's syndrome in adults
Cushing's disease in adults for whom pituitary surgery is not an option or has not been curative
Temozolomide (standard schedule, at least 3 cycles before assessing response), with radiotherapy where not previously given; PRRT for SSTR-positive tumours, bevacizumab or checkpoint inhibitors in trials or case series after temozolomide failure.